Neuralink signals high-volume implant manufacturing for 2026 as the patient count reaches twelve

Twelve is not a large number. It is a larger number than analysts were pricing a year ago, and it is the number on which Neuralink is now building a manufacturing case. As of September 2025, Neuralink had implanted its N1 array in twelve human participants, beginning with Noland Arbaugh in January 2024. The company has signalled a 2026 move toward high-volume production and a substantially automated surgical workflow — the implant to be threaded through the duraThe tough, outermost fibrous membrane protecting the brain and spinal cord. Penetrating neural implants must bypass it, either by incision or direct threading. by a next-generation R1 robot rather than around it — with Blindsight, its first visual-cortex variant, targeting its first patient within the same year.

For most of the brain-computer interfaceAny hardware that reads neural activity and translates it into control signals for an external system, or writes signals back into tissue. Current clinical systems are read-only and cortical. field, 2025 was a year of credentialing. Synchron, Precision Neuroscience, Paradromics, and Neuralink all expanded their first-in-human programmes at varying levels of invasiveness. Precision, founded by Neuralink co-founder Benjamin Rapoport, ran a surface-electrode thin-film array through its clinical milestones, arguing — persuasively to some — that penetrating electrodes are a decade-behind design choice. The field's technical debate is live and unsettled. What Neuralink's manufacturing posture signals is that it intends to resolve the debate commercially rather than scientifically, by shipping hardware at a cadence its peers cannot match.

The specific claim worth parsing is the surgical-automation claim. The original N1 implantation required a burr hole, duraThe tough, outermost fibrous membrane protecting the brain and spinal cord. Penetrating neural implants must bypass it, either by incision or direct threading. incision, and manual thread placement by the R1 robot under neurosurgeon supervision. The 2026 workflow Musk has described removes the dura incision and shortens the procedure to a form the company characterises as outpatient-compatible. Independent clinical evaluation of that workflow has not yet been published. The FDA pathway for a device moving from IDE early feasibility to a pivotal programmeA late-stage clinical trial designed to collect the definitive safety and efficacy evidence required for FDA device approval, typically following a smaller early feasibility study. is the gating constraint, and Neuralink has said little in public about its timeline for it.

The winners are the patients whose access to restoration-of-function devices depends on any one of these companies reaching manufacturing scale. The losers are the clinical and ethical frameworks which were designed for devices implanted into one patient a year, and which must now contend with a product category whose volume ambitions are orders of magnitude higher. The regulatory apparatus has not publicly signalled how it will triage that pipeline.

What the manufacturing posture forecloses is the framing of brain-computer interfaces as a research programme with a long tail to market. What it opens is the category's hardest question: who decides which indications, in what order, qualify for permanent intracranial hardware that the recipient cannot easily remove.